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Summary
 
To examine whether a retroviral disease can be controlled in animals in which cells from a re-
sistant strain coexist in a state of immunological tolerance with cells from a susceptible strain,
allophenic mice were constructed and infected with LP-BM5 murine leukemia viruses which
induce a fatal disorder, termed murine acquired immunodeficiency syndrome (MAIDS), char-
acterized by lymphoproliferation and immunodeficiency in susceptible inbred strains of mice.
We found that in two different strain combinations, resistance to MAIDS was contingent on
the presence in individual animals of 
 
.
 
50% of lymphocytes of resistant strain origin and corre-
lated with reduction or elimination of retrovirus. In contrast, animals harboring substantial, but less
than predominant, numbers of genetically resistant lymphocytes developed disease and died within
the same time frame as susceptible control mice with uncontained proliferation of retrovirus.
 
C
 
an a retroviral infection be controlled or eradicated by
the presence of immune cells that resist infection?
Current thought on therapies for human retroviral disease
considers the possibility that rendering at least part of a pa-
tient’s immune system resistant to infection will prove ben-
eficial (1, 2). To gain insight into the ability of resistant cells
to alter the outcome of retroviral disease, allophenic mice
were constructed from inbred strains of mice susceptible
and resistant to the syndrome of lymphoproliferation and
immunodeficiency induced by LP-BM5 murine leukemia
viruses (MuLV)
 
1
 
 termed murine acquired immunodefi-
ciency syndrome (MAIDS) (3–5). Induction of MAIDS is
dependent on expression of a replication defective virus,
BM5def, that encodes a unique Gag polyprotein (4, 6).
 
Allophenic mice (designated strain A
 
«
 
strain B) bear
cells of two different genotypes, with individual cells deriv-
ing from and expressing the characteristics of one donor
strain or the other, but not of both, as in an F
 
1
 
 animal. We
used as the susceptible donor the prototypic MAIDS-sensi-
tive strain, C57BL/6 (B6). The 129/SvJ (129) and A/J
strains were selected as resistant donors because they failed
to exhibit any signs of disease for 
 
>
 
38 wk after infection.
These studies establish that MAIDS can be controlled by
the presence of immune system cells that resist disease, and
suggest thresholds for the percentage of cells of resistant
genotype required to prevent progressive disease. Criti-
cally, assessment of retroviral burden over the course of dis-
ease reveals that although infection is initially established in
allophenics with significant numbers of cells of susceptible
genotype, those mice with a preponderance of cells of re-
sistant genotype are able to contain the viral burden and re-
main healthy.
 
Materials and Methods
 
Generation of Allophenic Mice and Determination of Lymphoid Chi-
merism.
 
The allophenic mice were constructed either by em-
bryo fusion at the four to eight cell stage of development in the
case of B6
 
«
 
A/J allophenics, or by injection of embryonic stem
cells into a blastocyst in the case of the B6
 
«
 
129 allophenics (7–9).
Percent chimerism of B6
 
«
 
129 allophenics was determined
from tail blood samples obtained before infection. PBL were ob-
tained from heparinized blood, and isolated on Lympholyte-M
(Cedarlane Labs. Ltd., Hornby, Ontario, Canada) cushions, stained
with fluorescent antibodies to the cell surface antigen Ly-9.1
 
1
 
Abbreviations used in this paper:
 
 BM5def, BM5 defective; HPRT, hypo-
xanthine phosphoribosyl transferase; MAIDS, murine acquired immuno-
deficiency syndrome; MCF, mink cell focus-forming; MuLV, murine
leukemia virus. 
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(PharMingen, San Diego, CA), and analyzed on a cell sorter (FACS
 
Ò
 
440; Becton Dickinson, San Jose, CA). B6 mice do not express
Ly-9.1 (10, 11).
Percent chimerism of B6
 
«
 
A/J allophenics was determined
from tail blood samples by subtracting the percent of H-2D
 
b
 
-
expressing cells from total cells. H2-D
 
b
 
, expressed on cells of B6
but not A/J origin, was detected with a biotin-labeled mAb
(PharMingen) and APC-avidin (Southern Biotechnology Assoc.,
Birmingham, AL) by flow cytometry.
To assess the stability of chimerism, four allophenics were left
uninfected. Chimerism was assessed at weeks 0 and 24 in three
mice and at weeks 0, 8, 15, and 24 in a fourth. Chimerism was
remarkably stable, varying by at most 6% from the initial evalua-
tion.
To assess whether chimerism in PBL reflected that of other
lymphoid compartments, we compared chimerism in PBL with
that in spleen. We found 
 
,
 
10% variation between the two. In-
deed, a close correlation in chimerism between spleen and pe-
ripheral blood of allophenics has been previously described (12).
We therefore used peripheral blood to assess chimerism because it
minimized both trauma to the mice and the possibility that the
course of disease would be altered by experimental manipulation.
 
Studies of Infected Mice.
 
Mice were judged to have MAIDS on
the basis of progressive lymphadenopathy and splenomegaly and
changes in cellular populations and cell surface antigens character-
istic of MAIDS: the development of a B220 dull population of
cells, excessive numbers of CD11b (Mac-1)
 
1
 
 cells, and the emer-
gence of a CD4
 
1
 
, Thy 1.2
 
2
 
 population of cells (13). Because
spleen biopsies were performed, spleen weights at death are not
presented, as they would not provide an accurate measure of lym-
phoproliferation.
Virus recovery was determined by infectious center assays (14–
16) using XC cell plaque assays in SC-1 cells for ecotropic
MuLV, and immunofluorescent focus induction using mono-
clonal antibody 514 (17) in 
 
Mus dunni
 
 cells (18) for mink cell fo-
cus-forming (MCF) MuLV.
mRNA for BM5 defective (BM5def) was detected by reverse
transcriptase-PCR using primers and the probe described previ-
ously (19, 20). PCR products were analyzed by Southern blot
hybridization with fluorescein-labeled probes. To control for
quantitative and qualitative variability of cDNAs, the housekeep-
ing gene hypoxanthine phosphoribosyl transferase (HPRT) was
transcribed and amplified for all samples. To determine the rela-
tive expression of BM5def in different samples, we established
standard curves for HPRT and BM5def by titration of cDNA
samples prepared from spleens of mice infected with LP-BM5 vi-
rus that had the highest signals for BM5def or HPRT expression
in initial screening. Amplification of HPRT for 24 cycles and of
BM5def for 23 cycles gave linear correlations between the
amounts of template cDNAs and PCR products (Fig.1). The in-
tensity of hybridizing bands was determined by densitometric
scanning (Hewlett-Packard Scanner; Hewlett-Packard Co., Palo
Alto, CA) (21). Data represent differences in transcript levels nor-
malized to HPRT expression and compared to a positive control
(cDNA prepared from RNA of B6 spleen 4 wk after inoculation
with LP-BM5 MuLV). Relative values are presented as follows:
 
1111
 
 
 
5
 
 100% of control; 
 
111
 
 
 
5
 
 70–90%; 
 
11
 
 
 
5
 
 40–60%;
 
1
 
 
 
5
 
 10–30%; trace 
 
5
 
 
 
,
 
10%; 
 
2
 
 
 
5
 
 undetectable.
For mice studied at more than one time point, the first sample
was from a hemisplenectomy, the second sample was from the re-
sidual spleen, and the third sample was from lymph node.
 
Statistical Analysis.
 
The statistical significance of the associa-
tion between 
 
<
 
50% lymphocytes of resistant strain origin and de-
velopment of disease, and 
 
.
 
50% lymphocytes of resistant strain
origin and resistance to disease was assessed by Fisher’s Exact Test
(StactXact3 software; CYTEL Software Corporation, Cam-
bridge, MA).
 
Results
 
Studies of Time to Disease or Death in Unmanipulated
B6
 
«
 
29 Mice Infected with LP-BM5 MuLV.
 
We first asked
whether induction of MAIDS could be controlled by the
presence of cells from the 129 strain of inbred mice. 129
mice are of the Fv-1
 
nr
 
 (22) genotype and therefore restrict
replication of the B-tropic helper viruses in LP-BM5
MuLV. Furthermore, they are also resistant to MAIDS de-
velopment following infection with BM5def pseudotyped
Figure 1. Correlation between input cDNA and HPRT or BM5def
RT-PCR signals. RNA isolated from the spleens of LP-BM5 infected
mice was reverse transcribed and twofold serial dilutions of the undiluted
cDNAs were amplified for 24 cycles for HPRT(A), and for 23 cycles for
BM5def(B). The PCR products were Southern blotted and detected by
hybridization with fluorescein-labeled probes. Signal strength was ana-
lyzed by densitometry. 
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with a N-tropic helper virus (23); the mechanism of this
resistance is not known.
The initial study determined time to lymphadenopathy
and time to death following infection of unmanipulated
B6
 
«
 
129 allophenics. To meaningfully assess these two
clinical endpoints of infection, mice were not subjected to
procedures such as splenic biopsy which have an impact on
the course of viral disease (Sechler, J.M.G., and A.S. Rosen-
berg,  unpublished observation). Instead, the mice were
bled only after development of lymphadenopathy for as-
sessment of cellular populations indicative of MAIDS. 
Four mice with 
 
,
 
50% PBL of 129 origin developed
lymphadenopathy and died in a time course similar to that
of fully susceptible B6 mice. Only the allophenic harboring
68% PBL of 129 origin failed to develop disease (Fig. 2, 
 
A
 
and 
 
B
 
). 10 additional B6
 
«
 
129 mice with primarily B6
PBL also developed lymphadenopathy secondary to MAIDS
in the same time frame as B6 mice, whereas 6 mice with
57–82% 129 PBL never developed lymphadenopathy and
remained healthy (Fig. 2 
 
C
 
). Association between develop-
ment of disease and having 
 
<
 
50% of lymphocytes of resis-
tant strain origin, and resisting disease and having 
 
.
 
50% of
lymphocytes of resistant strain origin, was highly significant
(
 
P
 
 
 
5
 
 0.0002 by Fisher’s Exact Test).
These data indicate that protection against MAIDS in
this strain combination requires that a majority of lymphoid
cells be of the resistant strain and that mice with lower fre-
quencies of 129 cells have no survival advantage over in-
bred susceptible animals. The frequency of cells from the
resistant strain required to prevent induction of MAIDS is
Figure 2. (A) Time to lymphadenopathy in B6 mice and in B6 « 129
chimeras after intraperitoneal inoculation with LP-BM5 MuLV. The per-
centage of PBL that express Ly-9.1, a lymphoid cell surface antigen
present on cells of 129 origin but not of B6 origin (10, 11), is shown un-
der the symbols representing individual chimeras, and was assessed prior
to infection. The open symbol indicates the chimera that did not develop
lymphadenopathy. (B) Time to death in B6 « 129 allophenics. The 68%
129 mouse was euthanized at the indicated timepoint and no evidence of
disease was found. (C) Outcome of infection in all B6 « 129 mice stud-
ied for >12 wk. Solid squares represent individual mice that developed
disease. Open squares represent mice that did not develop disease. Associ-
ation of .50% cells of 129 origin and resistance to disease is highly signif-
icant (P 5 0.002 by Fisher’s Exact Test). 
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z
 
60%, as suggested by the susceptible mouse with 62%
129 cells and three resistant mice with 57–59% of PBL
from strain 129.
 
Serial Studies of B6
 
«
 
129 Mice Infected with LP-BM5
MuLV.
 
To develop an understanding of the relationships
among percent chimerism, virus expression, and develop-
ment of MAIDS, we studied a series of B6
 
«
 
129 mice by
examining splenic biopsies taken soon after infection for
the presence of the three viruses that make up the LP-BM5
virus mixture and then observing the mice for development
of disease; some mice were biopsied serially (Table 1). Mice
were identified at autopsy as having MAIDS or not by
gross observations and FACS
 
Ò
 
 analysis of lymphoid tissues.
While all allophenics tested 4 wk after inoculation ex-
pressed infectious ecotropic MuLV indicating successful in-
fection of all animals, recovery of infectious MCF MuLV
was less common and generally correlated with high ex-
pression of BM5def.
Interestingly, detection of BM5def at this early timepoint
was not predictive of subsequent development of disease
(20). First, the two allophenics with 59% PBL of 129 origin
in which BM5def was detectable did not develop disease.
Second, the allophenic with 46% PBL of 129 origin, in
which BM5def was not detected at the 4 wk timepoint, did
go on to develop MAIDS as revealed by flow cytometry of
PBL 23 wk after inoculation. Since previous experience has
shown that mice with fully developed MAIDS uniformly
express BM5def at high levels (24; Morawetz, R., and
H.C. Morse, unpublished observations), we assume that in-
fection of this mouse early in disease was either at levels be-
low our limit of detection or localized to tissues not as-
sayed.
The B6
 
«
 
129 mouse with 59% 129 cells studied at three
timepoints after infection is of special interest. Tests showed
that a moderate proportion of spleen cells obtained at 4 wk
after infection produced infectious ecotropic virus, whereas
cells recovered at 19 wk from spleen and 35 wk from
lymph node produced no detectable virus. In addition,
transcripts for BM5def were detected in spleen at 4 and 19
wk but were present in lymph node at only trace levels at
 
Table 1.
 
Virus Assays and Documentation of MAIDS in B6
 
«
 
129 Allophenics
 
Mouse Virus Assays Documentation of
MAIDS (time
postinfection in wk) Weeks after
infection
ECO MCF BM5def
(RT-PCR)
[PFU or FFU
(Log
 
10
 
/10
 
7
 
 cells)]
B6 
 
« 129
 
%LY-9.1
 
1
 
46 4 2.0
 
,
 
1.3
 
2
 
19
57 4 1.0
 
,
 
1.3
 
2
 
Killed 05 wk NED
62 4 3.1 1.3
 
1111
 
19
82 4 1.0
 
,
 
1.3
 
2
 
Died 10 wk NED
 
*
 
22 4 4.5 2.0
 
1111
 
19 4.2 4.0
 
11
 
19
59 4 2.5
 
,
 
1.3
 
111
 
19
 
,
 
1
 
,
 
1.3
 
111
 
35
 
,
 
1
 
,
 
1.3 TR Killed 35 wk NED
59 13
 
,
 
1
 
,
 
1.3
 
1
 
Killed 13 wk NED
49 24 4.8 NT NT 24
68 24
 
,
 
1 NT NT Killed 24 wk NED
Controls
B6 4 3.8 2.5
 
1111
 
4
129SvJ 4
 
,
 
1
 
,1.3 2
19 ,1 ,1.3 2. 52 wk NED
Expression of ecotropic (ECO), mink cell focus-forming MCF, and BM5 defective (BM5def) MuLV in splenocytes (except for the third sample,
which is from LN) from B6 « 129 chimeras and control mice infected with LP-BM5 MuLV. Relative levels of BM5def transcripts were determined
as described in Materials and Methods. 1111 5 100% of control; 111 5 70–90%; 11 5 40–60%; 1 5 10–30%; trace (TR) 5 ,10%; 2 5
undetectable. NT, not tested. Documentation of MAIDS was based on criteria elaborated in Materials and Methods. All animals diagnosed with
MAIDS died of progressive disease. NED, no evidence of disease.
*Mouse was found dead of fight wounds.2105 Sechler et al.
35 wk. Thus, despite initial infection, the burden of both
ecotropic and defective viruses was reduced, and the mouse
remained healthy until killed.
Long-term disease-free survival was also associated with
undetectable ecotropic virus in the mouse with 68% 129
cells which was sacrificed at 24 wk after inoculation without
lymphadenopathy or splenomegaly. This contrasts with the
high level expression of helper virus in the mouse with
49% 129 cells which had MAIDS and was moribund when
tested at the same time after infection. Prolonged resistance
to MAIDS was thus associated with control of ecotropic
virus spread and limited expression of BM5def.
Studies of Time to Disease in B6«A/J Mice Infected with
LP-BM5 MuLV. To examine whether similar levels of
genotypically resistant cells are required for disease protec-
tion if resistance is predicated on an immunologic mecha-
nism, B6«A/J chimeras were assessed. The disease resis-
tance of A/J mice requires the presence of CD81 T cells
and is presumably immunologically mediated (25). In addi-
tion, A/J mice restrict replication of both the ecotropic and
BM5def components of the LP-BM5 virus mixture (26, 27).
PBL of B6«A/J mice ranged in chimerism from 3 to
97% A/J with 14 of 17 mice bearing predominantly B6
PBL (Fig. 3 B). Of eight unmanipulated chimeras (Fig. 3 A),
seven with cells of predominantly B6 origin developed
lymphadenopathy within the same time frame as infected
B6 and B6AF1 control animals. In contrast, the allophenic
with 54% PBL of A/J origin exhibited resistance to MAIDS
until sacrifice at 63 wk after infection. 
As with the B6«129 allophenics, an understanding of
the relationships among percent chimerism, virus expres-
sion, and development of MAIDS was sought. All 14
B6«A/J mice with ,51% A/J PBL developed MAIDS,
whereas three mice with .50% A/J cells did not (Fig. 3 B).
The mouse with 51% A/J cells had splenomegaly at the
time of biopsy 4 wk after infection, but did not progress to
peripheral lymphadenopathy by the time of a second bi-
opsy 19 wk later, although the spleen was still slightly en-
larged and had nodules. Together, these findings suggest
that about 50% PB cells of A/J origin are essential to medi-
ate disease resistance. Again, there was a highly significant
association between development of disease and having
<50% of lymphocytes of resistant strain origin, and resist-
ing disease and having .50% of lymphocytes of resistant
strain origin (P 5 0.0015 by Fisher’s Exact Test).
The relationship between virus expression and percent
chimerism in B6«A/J mice was generally consistent with
results in the B6«129 allophenics. In particular, the two
MAIDS-resistant mice showed a reduction in the fre-
quency of ecotropic-virus-producing cells between the
spleen samples obtained earlier and later in infection. In
contrast, the mice with 40 and 44% PBL of A/J origin
showed little or no ability to control expression of either
helper virus or BM5def (Table 2). Thus, as with resistant
B6«129 chimeras, resistant B6«A/J chimeras were clearly
infected, had an initial burst of virus replication, but were
able to contain retroviral burden.
Discussion
One approach to treatment of human retroviral disease
involves reconstructing the immune system with lympho-
cytes that cannot be infected to mediate critical immune
functions. Unfortunately, animal models to test such an ap-
Figure 3. (A)Time to lymphadenopathy in B6, B6AF1, and B6 « A/J mice after inoculation with LP-BM5 MuLV. The percentage of A/J cells in
PBL of the chimeras is shown beneath the symbols representing individual mice. The open symbol represents the chimera that did not develop lymphade-
nopathy. (B) Outcome of infection in B6 « A/J allophenics studied for >12 wk. Solid triangles represent mice that developed disease. Open triangles
represent mice that did not develop disease. Association of .50% cells of A/J origin and resistance to disease is highly significant (P 5 0.0015 by Fisher’s
Exact Test).2106 Resistance to Retroviral Disease in Allophenic Mice
proach for HIV or SIV are lacking. Thus, despite limita-
tions as a model of disease induced by HIV, we tested a
murine retroviral disease which shares some features of
human AIDS. Allophenic mice comprised of cells from
MAIDS-resistant and -susceptible strains were studied rather
than radiation bone marrow chimeras to avoid problems
associated with delayed repopulation of lymphocyte subsets
critical for induction and progression of disease. Thus, re-
sistance versus susceptibility was studied in a “best case”
scenario in which an intact but chimeric immune system
with mutual tolerance was present at the time of infection. 
Our results suggest that a critical balance in the propor-
tion of lymphoid cells from the MAIDS-resistant and -sen-
sitive strains determines whether mice infected with LP-
BM5 MuLV develop MAIDS or exhibit long-term resistance
to disease. Indeed, MAIDS was prevented or controlled only
in the chimeras that had a predominance of cells of the re-
sistant genotype at the time of infection; no significant ben-
efit with regard to disease progression or survival was con-
ferred on animals in which lymphoid cells of the resistant
genotype were in the minority.
It thus seems possible that a race between the rate of vi-
rus spread among cells of susceptible genotype and the rate
at which virus-specific effector cells and mechanisms are
activated determines the outcome of infection with LP-
BM5 MuLV. When the proliferation of virus-infected cells
outpaces the activation and expansion of effector mecha-
nisms, the animal develops lymphoproliferation and immu-
nodeficiency. This model predicts that disease develops in
chimeras with a large pool of genetically susceptible B cells,
shown to be the principal early targets of infection (28, 29),
coupled with a smaller pool of genotypically resistant effec-
tor cells. In these mice the frequency of virus-specific pre-
cursors would be limited, lessening the chance that suffi-
Table 2. Virus Assays and Documentation of MAIDS in B6«A/J Allophenics
Mouse Virus Assays Documentation of
MAIDS
(time postinfection in wk) Weeks after
infection
ECO MCF BM5def
(RT-PCR)
[PFU or FFU
(Log10/107 cells)]
B6 « A/J
%A/J
3 4 4.4 2.3 1111 4
22 4.5 4.2 NT
22 4 3.8 ,1.3 111 4
22 4.9 4.1 NT
30 12 4.2 3.0 111 4
27 3.9 4.3 111
30 34 3.7 4.2 1111 6
40 4 3.0 1.3 1111 4
22 4.5 4.1 NT
34 3.3 3.1 1111
44 4 2.0 1.3 1 8
22 2.3 4.1 NT
34 4.0 4.0 111
51 4 4.5 ,1.3 11 .52wk NED
23 2.0 1.3 11
54 12 1.3 TR TR Killed 63 wk NED
27 ,1T R T R
Controls
B6 4 3.8 2.5 1111 4
A/J 4 ,1 ,1.3 2
22 ,1 ,1.3 NT .52 wk NED
Expression of ecotropic (ECO), mink cell focus-forming MCF, and BM5def  MuLV in splenocytes from B6 « A/J chimeras and control mice in-
fected with LP-BM5 MuLV. Relative levels of BM5def transcripts were determined as described in Materials and Methods and legend for Table 1.
Documentation of MAIDS was based on criteria elaborated in Materials and Methods. All animals diagnosed with MAIDS died of progressive dis-
ease. NED, no evidence of disease.2107 Sechler et al.
cient virus-specific effectors could be generated to prevent
disease. In allophenics with a predominance of cells of re-
sistant genotype, there would be a sufficient level of virus-
specific effectors and/or effector mechanisms to contain vi-
rus spread and prevent development of disease.
An alternative view of the requirement for a majority of
resistant genotype cells to mediate resistance is based on the
suggestion that B6 mice may provide a factor such as a cy-
tokine necessary for disease induction (24, 30). Thus, resis-
tant allophenics may not have this factor in an amount suf-
ficient to facilitate disease progression, or the resistant strain
may provide a factor such as IL-12 (31) that inhibits disease
induction. Indeed, a genetically controlled negative regula-
tory factor has been implicated in resistance to induction of
erythroleukemia by Friend virus complex (32).
We can conclude that the presence of genetically resis-
tant immune system cells in sufficient numbers can confer
long-term resistance to retroviral disease, even though viral
integration and replication has occurred. This may have
important implications for novel approaches to therapy of
human retroviral disease.
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